Skip To Main Content
Busizwe Sibandze on Muck Rack

Busizwe Sibandze

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Busizwe

Contact Busizwe, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Targeted next-generation sequencing implementation in Eswatini identifies rifampicin and bedaquiline resistance undetected by routine diagnostic testing

|
By Debrah Vambe, Alexander Kay, Mangaliso Ziyane, Sein Sein Thi, Leonardo De Araujo, Viola Dreyer, Tanja Niemann Verified, Andrea Maurizio Cabibbe, Jennifer Furin, Lindokuhle Dlamini, Gugu Maphalala, Makhosazana Dlamini, Daniela Maria Cirillo, Anna M Mandalakas, Christoph Lange, Christian Utpatel, Sindisiwe Dlamini, Stefan Niemann Verified, Mdigo Thunzini, Busizwe Sibandze, Sijabu Masina, Tafadzwa Mazuruse, Thulani Jele, Bheki Mamba, Mbongeni Dube, Nomthandazo Lukhele, Sphiwe Ngwenya
| Nature Verified
Abstract In Eswatini, multidrug-resistant (MDR) Mycobacterium tuberculosis (Mtb) strains harbouring the rifampicin-resistance (RR) rpoB I491F mutation are missed by routine diagnostics, including GeneXpert MTB/RIF Ultra (Xpert Ultra), line probe assays (LPA), and mycobacterium growth indicator tube (MGIT) phenotypic drug susceptibility testing (pDST). To address this diagnostic gap, Eswatini introduced targeted next-generation sequencing (tNGS) in 2019.
Open in Who Shared Issue with article?
See all 1 articles